Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | HGFR |
Clinical data | |
Other names | LY2875358 |
ATC code |
|
Identifiers | |
CAS Number |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C6356H9810N1694O2014S48 |
Molar mass | 143719.12 g·mol−1 |
This drug was developed by Eli Lilly & Company.